MiMedx Group, Inc. (MDXG) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MDXG Revenue Growth
Revenue Breakdown (FY 2025)
MDXG's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
MDXG Revenue Analysis (2014–2025)
As of May 8, 2026, MiMedx Group, Inc. (MDXG) generated trailing twelve-month (TTM) revenue of $389.4 million, reflecting significant decline in growth of -33.1% year-over-year. The most recent quarter (Q1 2026) recorded $59.0 million in revenue, down 50.0% sequentially.
Looking at the longer-term picture, MDXG's 5-year compound annual growth rate (CAGR) stands at +11.0%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $418.6 million in 2025, representing a new all-time high.
Revenue diversification analysis shows MDXG's business is primarily driven by Surgical (100%). With over half of revenue concentrated in Surgical, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including OSUR (-47.3% YoY), TELA (+12.2% YoY), and APOG (+3.2% YoY), MDXG has underperformed the peer group in terms of revenue growth. Compare MDXG vs OSUR →
MDXG Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MDXGCurrent | $389M | -33.1% | +11.0% | 15.3% | |
 OSUR | $115M | -47.3% | -7.7% | -59.2% | |
 TELA | $69M | +12.2% | +35.0% | -49.2% | |
 APOG | $1.4B | +3.2% | +2.7% | 6.0% | |
 MASI | $1.5B | -14.4% | +5.9% | 20.5% |
MDXG Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $418.6M | +20.0% | $345.6M | 82.6% | $63.9M | 15.3% |
| 2024 | $348.9M | +8.5% | $288.8M | 82.8% | $58.9M | 16.9% |
| 2023 | $321.5M | +20.0% | $266.8M | 83.0% | $37.1M | 11.5% |
| 2022 | $267.8M | +10.7% | $219.5M | 82.0% | $-14,727,000 | -5.5% |
| 2021 | $242.0M | -2.5% | $202.4M | 83.6% | $-7,051,000 | -2.9% |
| 2020 | $248.2M | -17.0% | $208.9M | 84.2% | $-45,398,000 | -18.3% |
| 2019 | $299.3M | -16.7% | $256.2M | 85.6% | $-21,160,000 | -7.1% |
| 2018 | $359.1M | +11.8% | $322.7M | 89.9% | $-3,924,000 | -1.1% |
| 2017 | $321.1M | +31.1% | $285.9M | 89.0% | $46.2M | 14.4% |
| 2016 | $245.0M | +30.8% | $212.6M | 86.8% | $884K | 0.4% |
See MDXG's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MDXG Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MDXG vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMDXG — Frequently Asked Questions
Quick answers to the most common questions about buying MDXG stock.
Is MDXG's revenue growth accelerating or slowing?
MDXG revenue declined -33.1% year-over-year, contrasting with the 5-year CAGR of +11.0%. TTM revenue fell to $389M. This reverses the prior growth trend.
What is MDXG's long-term revenue growth rate?
MiMedx Group, Inc.'s 5-year revenue CAGR of +11.0% reflects the variable expansion pattern. Current YoY growth of -33.1% is below this long-term average.
How is MDXG's revenue distributed by segment?
MDXG reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.